MLICM
BHVN

Metropolitan Life Insurance Company (MetLife)’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,791
Closed -$573K – 2404
2022
Q3 		$573K Buy
3,791
+38
+1% +$5.63K 0.03% 462
2022
Q2 		$547K Buy
3,753
+264
+8% +$33.7K 0.02% 485
2022
Q1 		$414K Sell
3,489
-10,669
-75% -$1.33M 0.01% 578
2021
Q4 		$1.95M Sell
14,158
-379
-3% -$48.2K 0.03% 549
2021
Q3 		$2.02M Buy
+14,537
New +$1.82M 0.03% 502
2021
Q2 		– Sell
-13,055
Closed -$892K – 2973
2021
Q1 		$892K Sell
13,055
-450
-3% -$36.4K 0.01% 1033
2020
Q4 		$1.16M Sell
13,505
-665
-5% -$56.4K 0.02% 783
2020
Q3 		$921K Sell
14,170
-204
-1% -$13.4K 0.02% 794
2020
Q2 		$1.05M Buy
14,374
+1,829
+15% +$97.3K 0.02% 711
2020
Q1 		$427K Buy
12,545
+292
+2% +$13.4K 0.01% 1142
2019
Q4 		$667K Sell
12,253
-343
-3% -$17K 0.01% 1153
2019
Q3 		$526K Buy
12,596
+2,183
+21% +$92.2K 0.01% 1260
2019
Q2 		$456K Hold
10,413
– – 0.01% 1363
2019
Q1 		$536K Hold
10,413
– – 0.01% 1247
2018
Q4 		$385K Hold
10,413
– – 0.01% 1371
2018
Q3 		$391K Buy
+10,413
New +$383K 0.01% 1540

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s BHVN Position: Q4 2022 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 3,791 shares — an estimated $573K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in BHVN in Q3 2018 and held it in 16 quarters. The position peaked at $2.02M in Q3 2021. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 3,791 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $573K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2018 and held it in 16 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Biohaven Pharmaceutical Holding Company Ltd. position peaked at $2.02M in Q3 2021.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2022, filed 15 Feb 2023.